investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Targeting to Epigenetic Modications in ALL
Scott A Armstrong
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Scott A Armstrong
Memorial Sloan Kettering Cancer Center
New York, United States
Related projects
Guy S Salvesen
IAP Family Proteins and Cancer
Leukaemia
Pathology
Hematology and hematologic malignancies
Margaret A Goodell
Regulation of Hematopoietic Progenitors by de novo DNA Methylation
Leukaemia
David A Williams
Rac proteins in hematopoietic cell survival and function
Leukaemia
Hematology and hematologic malignancies
Clark W Distelhorst
Bcl-2 Function on the Endoplasmic Reticulum
Leukaemia
Pathology
Hematology and hematologic malignancies
Hao Yuan Kueh
Single cell analysis of hematopoietic cell fate determination
Leukaemia
Ross L Levine
Role of TET2 mutations in malignant transformation and acute myeloid leukemia
Leukaemia
Julie Aurore Losman
The Role of EglN1 and HIF in Normal Hematopoiesis and in Leukemia
Leukaemia
Joseph H Antin
A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT
Leukaemia
Michael Ryan Corces-Zimmerman
Functional significance of Pre-Leukemic HSC in Human Acute Myeloid Leukemia
Leukaemia